Skip to main content

Table 1 Characteristics of participants and rats in control (con) and Diabetic Nephropathy (DN) group

From: ets1 associates with KMT5A to participate in high glucose-mediated EndMT via upregulation of PFN2 expression in diabetic nephropathy

Human

Subjects

Age (Year)

BMI (kg/m2)

SBP (mmHg)

DBP (mmHg)

HbA1C (%)

FBG (mmol/l)

CREA (umol/l)

ALB (g/L)

CCr (ml/min)

24hUPQ (mg)

TP (g/L)

eGFR (ml/min/)

Normal control (n = 20)

Male: 9/20

58.3 ± 7.3

23.4 ± 3.3

118.9 ± 15.2

69.2 ± 8.1

5.2 ± 0.8

5.2 ± 0.5

58.3 ± 10.5

47.2 ± 5.2

101.9 ± 10.8

95.5 ± 10.2

69.5 ± 7.3

130.1 ± 25.2

DN stage 2 (n = 7)

Male: 3/7

57.4 ± 4.7

22.5 ± 2.3

133 ± 10.2

75.3 ± 8.3

6.8 ± 1.2

6.4 ± 0.8

100.2 ± 10.3

35.4 ± 3.2

80.9 ± 7.6

1499.4 ± 234.8

55.4 ± 6.1

71.4 ± 6.8

DN stage 3 (n = 7)

Male: 4/7

60.2 ± 4.4

24.6 ± 2.5

142.8 ± 12.1

78.3 ± 8.2

7.2 ± 2.0

7.2 ± 2.3

155.9 ± 12.4

32.2 ± 2.9

65.5 ± 7.1

4233.4 ± 359.0

50.8 ± 5.0

48.5 ± 6.5

DN stage 4 (n = 6)

Male: 3/6

59.1 ± 5.9

21 ± 4.3

147.3 ± 6.2

85.1 ± 6.9

8.9 ± 2.5

9.2 ± 3.1

265.8 ± 20.9

27.5 ± 3.6

39.8 ± 4.6

6750.4 ± 675.3

45.7 ± 8.0

23.4 ± 5.1

Rats

Variables

Con

DM

P-value

CREA (umol/l)

21.0 ± 2.2

39.7 ± 9.7

 < 0.0001

UREA (mmol/l)

2.3 ± 0.2

6.4 ± 1.1

 < 0.0001

24hUTP (mg)

31.7 ± 4.5

357.9 ± 70.3

 < 0.0001

  1. Data are presented as means ± SD. BMI (Body Mass Index), SBP (systolic blood pressure), DBP (diastolic blood pressure), HbA1c (glycated hemoglobin), FBG (fasting blood glucose), CREA (creatinine), ALB (albumin), CCr (Creatinine Clearance), 24hUPQ (24-h urinary protein quantity), TP (Total Protein), eGFR (Estimated Glomerular Filtration Rate)